Sepracor Plans April 4 Lunesta Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Sepracor will launch the insomnia agent upon same-day publication of the final rule designating Lunesta as a Schedule IV controlled substance. More than 40,000 retail pharmacies already have placed orders for eszopiclone, the company says.
You may also be interested in...
GSK Gains EU Rights To Lunesta Through Deal With Sepracor
GSK will market the sleep aid as Lunivia in Europe upon approval, which is anticipated in the second half of 2008.
GSK Gains EU Rights To Lunesta Through Deal With Sepracor
GSK will market the sleep aid as Lunivia in Europe upon approval, which is anticipated in the second half of 2008.
Sepracor Signs Agreement With Eisai To Market Lunesta In Japan
Eisai will develop and market Sepracor's insomnia treatment Lunesta (eszopiclone) in Japan under an in-licensing agreement announced by the companies July 26